Teva Clinches Third Place In CGRP Race With A Phase III Migraine Win
With a likely third place finish in the race to bring a CGRP inhibitor to market for the prevention of migraine headaches, Teva needs something to differentiate its product. Quarterly subcutaneous dosing may help fremanezumab become a fan favorite.
You may also be interested in...
Another hectic 12 months are anticipated at the US FDA as it is set to give its verdict on no fewer than 40 products in 2018. Here Scrip takes a look at 10 of the more interesting candidates approaching the market for the first time.
Institute for Clinical and Economic Review plans to evaluate the cost effectiveness of gene therapy, CAR-T drugs and tissue-agnostic cancer drugs, among other treatments, in 2018.
Part two of Scrip's preview of first quarter earnings: product launches, management priorities, pricing strategies and biosimilar competition are key themes at the half-year mark.